HC Wainwright Reiterates Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 379.62% from the stock’s current price.

Checkpoint Therapeutics Stock Up 2.2 %

NASDAQ CKPT opened at $4.17 on Wednesday. The firm has a market cap of $203.62 million, a PE ratio of -2.27 and a beta of 1.34. Checkpoint Therapeutics has a 52 week low of $1.36 and a 52 week high of $4.50. The company has a 50 day moving average price of $3.27 and a 200 day moving average price of $2.57.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). On average, equities research analysts anticipate that Checkpoint Therapeutics will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Checkpoint Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Magnus Financial Group LLC boosted its position in Checkpoint Therapeutics by 12.9% in the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock worth $78,000 after purchasing an additional 4,000 shares in the last quarter. Choreo LLC boosted its holdings in Checkpoint Therapeutics by 12.2% during the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock worth $133,000 after buying an additional 7,080 shares in the last quarter. PVG Asset Management Corp boosted its holdings in Checkpoint Therapeutics by 9.2% during the third quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock worth $336,000 after buying an additional 12,676 shares in the last quarter. Virtu Financial LLC acquired a new stake in Checkpoint Therapeutics during the third quarter valued at $30,000. Finally, XTX Topco Ltd purchased a new position in Checkpoint Therapeutics in the second quarter valued at $34,000. 22.00% of the stock is currently owned by institutional investors and hedge funds.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.